Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
10.3346/jkms.2001.16.1.69
- Author:
Jung Hee LEE
1
;
Je Hwan LEE
;
Tae Won KIM
;
Kyoo Hyung LEE
;
Yoon Koo KANG
;
Jung Shin LEE
;
Sang Hee KIM
;
Hee Cheol KIM
;
Chang Sik YU
;
Jin Cheon KIM
;
Woo Kun KIM
Author Information
1. Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Colorectal Neoplasms;
Oxaliplatin;
Fluorouracil;
Leucovorin
- MeSH:
Adult;
Aged;
Antineoplastic Agents, Combined/therapeutic use*;
Antineoplastic Agents, Combined/adverse effects;
Colorectal Neoplasms/mortality;
Colorectal Neoplasms/drug therapy*;
Disease-Free Survival;
Female;
Fluorouracil/administration & dosage;
Human;
Leucovorin/administration & dosage;
Male;
Middle Age;
Organoplatinum Compounds/administration & dosage
- From:Journal of Korean Medical Science
2001;16(1):69-74
- CountryRepublic of Korea
- Language:English
-
Abstract:
There has been no standard therapy for patients with metastatic colorectal cancer who have failed to first-line fluorouracil-based treatment. The present study was designed to assess the efficacy and toxicities of a combination of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin in fluoropyrimidine-pretreated patients with metastatic colorectal cancer. Chemotherapy consisted of oxaliplatin 85 mg/m2 on day 1, followed by leucovorin 20 mg/m2 and 5-FU 1,200 mg/m2 on days 1 and 2. Treatment courses were repeated every two weeks. Thirty-nine patients were enrolled in this study. All patients previously received fluoropyrimidine-based chemotherapy. Thirty-one patients were assessable for response and 33 for treatment toxicity. Six patients required dose reduction of 5-FU due to grade III/IV cytopenia. Nausea/vomiting and peripheral neuropathy were common non-hematologic toxicities. Overall response rate was 42.0% including 3 complete response and 10 partial response. The median response duration was 91 days (range, 28-224+). The median duration of progression-free survival was 132 days (range, 40-308). A combination of oxaliplatin, 5-FU, and leucovorin showed high response rate in fluoropyrimidine-pretreated patients with metastatic colorectal cancer, but the duration of response was relatively short. It may be worthwhile to explore its therapeutic potential in the first-line treatment setting.
